CareASSIST is here to help you get the information and support you need. In addition to the program offerings, you may also find the following downloads and online resources helpful.
The CareASSIST application covers all aspects of the program: Access and Reimbursement, Financial Assistance, and Resource Support. Follow the directions on the form to apply, or call 1-833-WE+CARE (1-833-930-2273) to get started.
The CareASSIST brochure contains an overview of the program and its offerings.
The CareASSIST Copay Program overview brochure describes the program and its requirements.
An overview of potential sources of prescription assistance.
Certain patients may require information or assistance beyond what CareASSIST may offer. Below are links to external organizations that may be able to help, or you can call 1-833-WE+CARE (1-833-930-2273) to learn about alternate coverage options.
Learn about Medicaid in your state and if you may be eligible.
Learn about Medicare and prescription drug coverage, eligibility, and how to access the care you may need.
Find help for insurance and healthcare access problems.
Offers help and hope to people with chronic or life-threatening illnesses for whom cost limits access to breakthrough medical treatments.
The first and largest myeloma-specific charity in the world. With more than 525,000 members in 140 countries, the International Myeloma Foundation (IMF) serves patients with myeloma, family members, and the medical community. The IMF provides a wide range of programs in the areas of research, education, support, and advocacy.
Because its only motivation is to find a cure, the Multiple Myeloma Research Foundation is unencumbered in its ability to identify the barriers to progress, develop models to overcome them, and help evolve the industry through technologies that foster collaboration and leverage the collective power of the entire community.
Independent, up-to-date news and information for the multiple myeloma community.
A nationwide, community-based voluntary health organization dedicated to eliminating cancer as a major health problem.
A global network offering quality cancer support to millions of people touched by cancer, available online and at community-based centers and hospitals.
A not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education.
A leading national organization dedicated to providing free support services and financial assistance to anyone affected by cancer.
A united community for multiple myeloma patients, caregivers, medical professionals, and supporters.
The mission of the Leukemia & Lymphoma Society (LLS) is: cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. The LLS exists to find cures and ensure access to treatments for blood cancer patients. The LLS is the voice for all blood cancer patients, and works to ensure access to treatment.
SARCLISA is a prescription medicine used in combination with:
It is not known if SARCLISA is safe and effective in children.
Do not receive SARCLISA if you have a history of a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA (see the list of ingredients in the full Prescribing Information).
Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:
Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after your last dose of SARCLISA. Talk to your healthcare provider about birth control methods that you can use during this time.
Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines. Especially tell your healthcare provider if you have ever taken a medicine for your heart.
How will I receive SARCLISA?
– In cycle 1, SARCLISA is usually given weekly.
– Starting in cycle 2, SARCLISA is usually given every 2 weeks.
What are the possible side effects of SARCLISA?
SARCLISA may cause serious side effects, including:
Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each dose of SARCLISA.
Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA if you have an infusion reaction.
Get medical help right away if you develop any of the following symptoms of infusion reaction during or after an infusion of SARCLISA:
shortness of breath, wheezing, or trouble breathing
swelling of the face, mouth, throat, or tongue
dizziness, lightheadedness, or fainting
rash or itching
runny or stuffy nose
Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help increase your white blood cell counts during treatment with SARCLISA.
Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.
swelling of your ankles, feet, or legs
The most common side effects of SARCLISA in combination with pomalidomide and dexamethasone include:
The most common side effects of SARCLISA in combination with carfilzomib and dexamethasone include:
These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.